๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia

โœ Scribed by Kevin E. Sanders; Chul S. Ha; Jorge E. Cortes-Franco; Charles A. Koller; Hagop M. Kantarjian; James D. Cox


Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
68 KB
Volume
100
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

BACKGROUND

Although central nervous system (CNS) prophylaxis in patients with leukemia has reduced the incidence of CNS disease recurrence, it still is reported to occur in approximately 5โ€“10% of cases, resulting in a median survival of 6 months. Craniospinal irradiation (CSI) has been shown to improve survival in children who develop a CNS recurrence of acute lymphocytic leukemia (ALL). However, to the authors' knowledge, the role of CSI in adults with a CNS recurrence of leukemia is unknown.

METHODS

A retrospective review of adult patients treated with CSI for a CNS recurrence of leukemia identified 16 patients treated between 1986 and 2001. The median age of the patients was 34 years (range, 16โ€“58 years). The diagnoses included seven patients with acute myelogenous leukemia (AML), eight patients with ALL, and one patient with chronic myelogenous leukemia in blast crisis. All patients had achieved a complete disease remission prior to the CNS recurrence. Eleven patients had an isolated CNS recurrence and 5 patients had concurrent disease identified in the blood/bone marrow. The median dose of radiation was 24 grays (Gy) (range, 18โ€“34.5 Gy) to the cranium and 18 Gy (range, 15โ€“30 Gy) to the spine. The median fraction size was 1.8 Gy (range, 1.5โ€“2.0 Gy) to the cranium and 1.5 Gy (range, 1.5โ€“2.0 Gy) to the spine. Fifteen patients were also treated with intrathecal chemotherapy.

RESULTS

One patient failed to complete radiation treatment because of disease progression. Thirteen patients achieved a complete response in the cerebrospinal fluid (CSF). The median time to disease progression was 3 months from the first day of CSI and 7 months from CNS recurrence. The median survival was 4 months and 9 months, respectively. No CNS recurrences occurred, but there were 11 bone marrow failures, 2 patients without recurrence at > 5 years, and 3 deaths without a documented site of failure. Thirteen patients had no evidence of disease in the CSF until their death or the time of last followโ€up.

CONCLUSIONS

CSI with or without intrathecal chemotherapy appears to be effective at eliminating leukemia in the craniospinal axis. However, the eradication of disease in the CNS was not found to be effective at preventing disease recurrence in the bone marrow, and despite improved control of disease in the CNS, adult patients with a CNS recurrence still had a poor prognosis. Furthermore, the rapidly fatal course of disease prevented an assessment of the durability of CNS response to irradiation. Cancer 2004. ยฉ 2004 American Cancer Society.


๐Ÿ“œ SIMILAR VOLUMES


Central nervous system recurrence in adu
โœ Juan-Manuel Sancho; Josep-Maria Ribera; Albert Oriol; Jesus-Maria Hernandez-Riva ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 120 KB ๐Ÿ‘ 2 views

## Abstract Recurrence of acute lymphoblastic leukemia (ALL) in the central nervous system (CNS) confers a poor prognosis, although to the authors' knowledge, only a few studies have analyzed this issue in adults. For the current study, the authors analyzed the frequency, predictive factors, and pr

The role of systemic high-dose cytarabin
โœ Enrica Morra; Mario Lazzarino; Ercole Brusamolino; Guido Pagnucco; Carlo Castagn ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 701 KB

Background. Given the good penetration of systemic high-dose cytarabine (HDara-C) into the cerebrospinal fluid (CSF), this approach was used to treat patients with central nervous system (CNS) leukemia, either isolated or with concurrent extraneurologic disease (END). Methods. From 1983 to 1991,46